Published in Cardiovasc Res on February 14, 2006
The association between cortisol response to mental stress and high-sensitivity cardiac troponin T plasma concentration in healthy adults. J Am Coll Cardiol (2013) 1.50
The physiological impact of the serum and glucocorticoid-inducible kinase SGK1. Curr Opin Nephrol Hypertens (2009) 1.35
Therapeutic manipulation of glucocorticoid metabolism in cardiovascular disease. Br J Pharmacol (2009) 1.18
Dual role for glucocorticoids in cardiomyocyte hypertrophy and apoptosis. Endocrinology (2012) 1.09
Ubiquitin-proteasome degradation of serum- and glucocorticoid-regulated kinase-1 (SGK-1) is mediated by the chaperone-dependent E3 ligase CHIP. Biochem J (2006) 0.99
Hexose-6-phosphate dehydrogenase and 11beta-hydroxysteroid dehydrogenase-1 tissue distribution in the rat. Endocrinology (2007) 0.95
Cardiac corticosteroid receptors mediate the enlargement of the ovine fetal heart induced by chronic increases in maternal cortisol. J Endocrinol (2008) 0.84
Glucocorticoid signaling in the heart: A cardiomyocyte perspective. J Steroid Biochem Mol Biol (2015) 0.84
Blockade of glucocorticoid receptors with RU486 attenuates cardiac damage and adipose tissue inflammation in a rat model of metabolic syndrome. Hypertens Res (2015) 0.83
Dexamethasone Treatment of Newborn Rats Decreases Cardiomyocyte Endowment in the Developing Heart through Epigenetic Modifications. PLoS One (2015) 0.82
Getting to the heart of intracellular glucocorticoid regeneration: 11β-HSD1 in the myocardium. J Mol Endocrinol (2016) 0.78
A transgenic platform for testing drugs intended for reversal of cardiac remodeling identifies a novel 11βHSD1 inhibitor rescuing hypertrophy independently of re-vascularization. PLoS One (2014) 0.77
Lipid raft- and protein kinase C-mediated synergism between glucocorticoid- and gonadotropin-releasing hormone signaling results in decreased cell proliferation. J Biol Chem (2014) 0.76
Attenuation of cold stress-induced exacerbation of cardiac and adipose tissue pathology and metabolic disorders in a rat model of metabolic syndrome by the glucocorticoid receptor antagonist RU486. Nutr Diabetes (2016) 0.76
ATRX interacts with H3.3 in maintaining telomere structural integrity in pluripotent embryonic stem cells. Genome Res (2010) 3.46
Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. Cancer Discov (2014) 2.74
mTOR-dependent regulation of ribosomal gene transcription requires S6K1 and is mediated by phosphorylation of the carboxy-terminal activation domain of the nucleolar transcription factor UBF. Mol Cell Biol (2003) 2.68
Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53. Cancer Cell (2012) 2.29
Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth. Cancer Res (2010) 2.18
Coordinate regulation of ribosome biogenesis and function by the ribosomal protein S6 kinase, a key mediator of mTOR function. Growth Factors (2007) 1.89
Expression of constitutively active angiotensin receptors in the rostral ventrolateral medulla increases blood pressure. Hypertension (2006) 1.81
An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice. J Clin Invest (2012) 1.79
MAD1 and c-MYC regulate UBF and rDNA transcription during granulocyte differentiation. EMBO J (2004) 1.64
The renin-angiotensin system and cancer: old dog, new tricks. Nat Rev Cancer (2010) 1.62
Second AKT: the rise of SGK in cancer signalling. Growth Factors (2010) 1.57
Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers. PLoS One (2011) 1.57
UBF levels determine the number of active ribosomal RNA genes in mammals. J Cell Biol (2008) 1.57
AKT promotes rRNA synthesis and cooperates with c-MYC to stimulate ribosome biogenesis in cancer. Sci Signal (2011) 1.49
LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin. Cancer Res (2012) 1.39
A specific role for AKT3 in the genesis of ovarian cancer through modulation of G(2)-M phase transition. Cancer Res (2006) 1.26
Dysregulation of the basal RNA polymerase transcription apparatus in cancer. Nat Rev Cancer (2013) 1.26
Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy. Circ Res (2003) 1.18
The role of UBF in regulating the structure and dynamics of transcriptionally active rDNA chromatin. Epigenetics (2009) 1.17
Translational control of c-MYC by rapamycin promotes terminal myeloid differentiation. Blood (2008) 1.11
A novel mouse model of atherosclerotic plaque instability for drug testing and mechanistic/therapeutic discoveries using gene and microRNA expression profiling. Circ Res (2013) 1.11
Adenoviral-directed expression of the type 1A angiotensin receptor promotes cardiomyocyte hypertrophy via transactivation of the epidermal growth factor receptor. Circ Res (2002) 1.08
The nucleolus: an emerging target for cancer therapy. Trends Mol Med (2013) 1.07
Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines. Pigment Cell Melanoma Res (2014) 1.05
Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomas. Blood (2013) 1.02
Urotensin II promotes hypertrophy of cardiac myocytes via mitogen-activated protein kinases. Mol Endocrinol (2004) 1.02
Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors. Eur J Cancer (2013) 1.02
The mTORC1 inhibitor everolimus prevents and treats Eμ-Myc lymphoma by restoring oncogene-induced senescence. Cancer Discov (2012) 1.01
c-MYC coordinately regulates ribosomal gene chromatin remodeling and Pol I availability during granulocyte differentiation. Nucleic Acids Res (2010) 1.01
Sex hormones and cardiomyopathic phenotype induced by cardiac beta 2-adrenergic receptor overexpression. Endocrinology (2003) 1.00
AKT-independent PI3-K signaling in cancer - emerging role for SGK3. Cancer Manag Res (2013) 0.99
Functional analysis of genes in regions commonly amplified in high-grade serous and endometrioid ovarian cancer. Clin Cancer Res (2013) 0.95
Hfp inhibits Drosophila myc transcription and cell growth in a TFIIH/Hay-dependent manner. Development (2010) 0.95
Autophagy induction is a Tor- and Tp53-independent cell survival response in a zebrafish model of disrupted ribosome biogenesis. PLoS Genet (2013) 0.94
Increased plasma concentrations of anterior gradient 2 protein are positively associated with ovarian cancer. Clin Sci (Lond) (2010) 0.94
Cardiovascular role of urotensin II: effect of chronic infusion in the rat. Peptides (2004) 0.93
Expression, regulation and putative nutrient-sensing function of taste GPCRs in the heart. PLoS One (2013) 0.91
Adrenomedullin expression in rat uterus is correlated with plasma estradiol. Am J Physiol Endocrinol Metab (2002) 0.89
Progression from first symptom to diagnosis in childhood brain tumours. Eur J Pediatr (2011) 0.89
A functional siRNA screen identifies genes modulating angiotensin II-mediated EGFR transactivation. J Cell Sci (2013) 0.88
Evaluation of midkine and anterior gradient 2 in a multimarker panel for the detection of ovarian cancer. J Exp Clin Cancer Res (2010) 0.88
Signaling to the ribosome in cancer--It is more than just mTORC1. IUBMB Life (2011) 0.88
Drosophila ribosomal protein mutants control tissue growth non-autonomously via effects on the prothoracic gland and ecdysone. PLoS Genet (2011) 0.87
Unravelling the molecular complexity of GPCR-mediated EGFR transactivation using functional genomics approaches. FEBS J (2013) 0.87
Targeting RNA polymerase I transcription and the nucleolus for cancer therapy. Expert Opin Ther Targets (2013) 0.85
Relative Expression Levels Rather Than Specific Activity Plays the Major Role in Determining In Vivo AKT Isoform Substrate Specificity. Enzyme Res (2011) 0.84
Inositol polyphosphate 1-phosphatase is a novel antihypertrophic factor. J Biol Chem (2002) 0.83
Determination of the exact molecular requirements for type 1 angiotensin receptor epidermal growth factor receptor transactivation and cardiomyocyte hypertrophy. Hypertension (2011) 0.83
Urotensin II: the old kid in town. Trends Endocrinol Metab (2004) 0.83
UTP transactivates epidermal growth factor receptors and promotes cardiomyocyte hypertrophy despite inhibiting transcription of the hypertrophic marker gene, atrial natriuretic peptide. J Biol Chem (2003) 0.82
11Beta-hydroxysteroid dehydrogenase 1 transforms 11-dehydrocorticosterone into transcriptionally active glucocorticoid in neonatal rat heart. Endocrinology (2002) 0.82
Tackling the EGFR in pathological tissue remodelling. Pulm Pharmacol Ther (2005) 0.82
Comparison of self-reported late effects with medical records among survivors of childhood cancer. Eur J Cancer (2010) 0.81
Co-expression of adrenomedullin and adrenomedullin receptors in rat epididymis: distinct physiological actions on anion transport. Biol Reprod (2003) 0.81
A phospho-proteomic screen identifies novel S6K1 and mTORC1 substrates revealing additional complexity in the signaling network regulating cell growth. Cell Signal (2011) 0.80
Hfp, the Drosophila homolog of the mammalian c-myc transcriptional-repressor and tumor suppressor FIR, inhibits dmyc transcription and cell growth. Fly (Austin) (2011) 0.80
Effect of dominant-negative epidermal growth factor receptors on cardiomyocyte hypertrophy. J Recept Signal Transduct Res (2006) 0.79
AKT signalling is required for ribosomal RNA synthesis and progression of Eμ-Myc B-cell lymphoma in vivo. FEBS J (2013) 0.79
Cardiac hypertrophy in vivo is associated with increased expression of the ribosomal gene transcription factor UBF. FEBS Lett (2003) 0.78
Protein depletion using IgY from chickens immunised with human protein cocktails. Prep Biochem Biotechnol (2009) 0.77
AGR2 expression in ovarian tumours: a potential biomarker for endometrioid and mucinous differentiation. Pathology (2013) 0.77
Unexpected role of CDK4 in a G2/M checkpoint. Cell Cycle (2015) 0.75
Chromatin organization and expression. Genome Biol (2008) 0.75